888 results on '"Malyszko, Jolanta"'
Search Results
202. Serotonergic mechanisms are involved in the hemostatic action of erythropoietin in uremic patients
203. Same rhythm, different song—approaches to atrial fibrillation management by cardiologists and nephrologists.
204. Identifying critically important cardiovascular outcomes for trials in hemodialysis: an international survey with patients, caregivers and health professionals.
205. Evaluating hydrogen ion mobilization during hemodialysis using only predialysis and postdialysis blood bicarbonate concentrations
206. Labile plasma iron levels in chronic hemodialysis patients treated by intravenous iron supplementation.
207. Takotsubo syndrome - fatal prognosis of patients with low body mass index in 5-year follow-up.
208. Mild cognitive impairment and kidney disease: clinical aspects.
209. APPROACH TO A PATIENT WITH HEPATITIS C: DIAGNOSIS AND PRETREATMENT ASSESSMENT.
210. The clinical implication of monoclonal gammopathies: monoclonal gammopathy of undetermined significance and of renal significance
211. The ERA-EDTA today and tomorrow: a progress document by the ERA-EDTA Council
212. The Potential Impact of Sirtuin 1 Protein on Premature Ovarian Insufficiency
213. Cardiovascular risk in chronic kidney disease: what is new in the pathogenesis and treatment?
214. ERA-EDTA invests in transformation to greener health care
215. Patients with Atrial Fibrillation and Chronic Kidney Disease More Often Undergo Angioplasty of Left Main Coronary Artery – a 867 Patient Study
216. Adhering to the principles of clinical pharmacology - the correct fixed combinations of antihypertensive drugs
217. Iron therapy in heart failure patients without anaemia: possible implications for chronic kidney disease patients
218. Endocan Concentration in Patients With Primary Hypertension
219. Post-transplant lymphoproliferative disorder: risk factors and management.
220. Telomere attrition, kidney function, and prevalent chronic kidney disease in the United States
221. Atrial fibrillation in kidney transplant recipients: is there a place for the novel drugs?
222. MP696INTRAVENOUS PARICALCITOL, ORAL CINACALCET OR COMBINATION OF BOTH AGENTS - EFFECTIVENESS OF DIFFERENT STRATEGIES OF SECONDARY HYPERPARATHYROIDISM TREATMENT IN HEMODIALYZED PATIENTS
223. MP114THE CONCENTRATION OF ADROPIN AND IRISIN IN PATIENTS WITH PRIMARY HYPERTENSION
224. MP621THE RELATIONSHIP BETWEEN RENALASE TOGETHER WITH CATECHOLAMINES AND ANTI-AGING FACTORS - SIRTUIN 1 AND ALPHA-KLOTHO IN HEMODIALYSIS PATIENTS
225. Fibroblast growth factor 23, iron and inflammation – are they related in early stages of chronic kidney disease?
226. Age influence on renalase and catecholamines concentration in hypertensive patients, including maintained dialysis
227. The clinical implication of monoclonal gammopathies: monoclonal gammopathy of undetermined significance and of renal significance.
228. OS 01-02 ENDOCAN LEVEL IN ESSENTIAL HYPERTENSION
229. MPS 05-05 HIGH PERFORMANCE LIQUID CHROMATOGRAPHY MEASURED METABOLITES OF ENDOGENOUS CATECHOLAMINES AND THEIR RELATIONS TO CHRONIC KIDNEY DISEASE AND HIGH BLOOD PRESSURE IN HEART TRANSPLANT RECIPIENTS
230. Matrix Metalloproteinase Neutrophil Gelatinase-Associated Lipocalin Complex Predicts Atrial Fibrillation Recurrence after Electrical Cardioversion in Obese Patients
231. Emerging drugs for the treatment of kidney disease-induced anemia
232. SP367ZONULIN, INFLAMMATION AND IRON STATUS IN EARLY STAGES OF CHRONIC KIDNEY DISEASE
233. SP116ENDOCAN CONCENTRATION IN HYPERTENSIVE PATIENTS
234. Effects of dialyzer reuse on dialysis adequacy, anemia control, erythropoieting-stimulating agents use and phosphate level
235. Comorbidities on kidney transplantation waiting list relative to the status of the potential recipient
236. Atrial fibrillation in kidney transplant recipients: is there a place for the novel drugs?
237. The ERA-EDTA today and tomorrow: a progress document by the ERA-EDTA Council.
238. Endocan Concentration in Patients With Primary Hypertension.
239. Comorbidities on kidney transplantation waiting list relative to the status of the potential recipient.
240. Adhering to the principles of clinical pharmacology - the correct fixed combinations of antihypertensive drugs.
241. Zonulin, inflammation and iron status in patients with early stages of chronic kidney disease.
242. Do CHA2 DS2 VASc and HAS-BLED scores influence ‘real-world’ anticoagulation management in atrial fibrillation? 1556 patient registry from the reference cardiology centre
243. Cardiorenal Syndrome and the Role of the Bone-Mineral Axis and Anemia
244. Biomarkers of delayed graft function as a form of acute kidney injury in kidney transplantation
245. The growth of acute kidney injury: Eastern European perspective
246. FP094RENALASE AND CATECHOLAMINES IN ELDERLY PATIENTS WITH HYPERTENSION IN RELATION TO KIDNEY FUNCTION
247. FP797ENDOCAN SERUM LEVELS IN HEMODIALYSIS PATIENTS BEFORE AND DURING THE PROCEDURE WITH TWO DIFFERENT DIALYSIS MEMBRANES
248. FP102IS THERE AN AGE INFLUENCE ON RENALASE AND CATECHOLAMINES CONCENTRATION IN PATIENTS WITH HYPERTENSION?
249. Renalase is Removed by Kidneys and During Dialysis – Excess Related to CKD Complications?
250. Renalase, kidney and cardiovascular disease: Are they related or just coincidentally associated?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.